683 Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

683 Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.3M	Sell	1,530,000 -120,000	-7%	-$1.69M	1.11%	19
2025 Q4	$19.9M	Sell	1,650,000 -110,000	-6%	-$1.49M	0.87%	24
2025 Q3	$23.9M	Sell	1,760,000 -400,000	-19%	-$3.76M	1.25%	23
2025 Q2	$13.8M	Sell	2,160,000 -251,400	-10%	-$1.22M	0.91%	28
2025 Q1	$8.54M	Buy	2,411,400 +481,400	+25%	+$1.71M	0.59%	50
2024 Q4	$7.3M	Sell	1,930,000 -70,000	-4%	-$329K	0.45%	53
2024 Q3	$6.48M	Buy	2,000,000 +498,129	+33%	+$1.12M	0.49%	53
2024 Q2	$2.85M	Buy	+1,501,871	New	+$2.91M	0.22%	79
2022 Q3	–	Sell	-677,714	Closed	-$13M	–	242
2022 Q2	$13M	Hold	677,714	–	–	0.92%	35
2022 Q1	$7.68M	Buy	+677,714	New	+$15.3M	0.41%	65

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

683 Capital Management's AMLX Position: Q1 2026 in Review

683 Capital Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 7.3% in Q1 2026, selling an estimated $1.69M and leaving 1,530,000 shares worth $21.3M. The position accounts for 1.11% of the portfolio, ranked #19.

683 Capital Management first reported a position in AMLX in Q1 2022 and has held it in 10 quarters since. The position peaked at $23.9M in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

683 Capital Management held 1,530,000 shares of Amylyx Pharmaceuticals worth $21.3M as of Q1 2026.
683 Capital Management sold 120,000 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $1.69M.
Amylyx Pharmaceuticals made up 1.11% of 683 Capital Management's portfolio in Q1 2026, its #19 holding.
683 Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
683 Capital Management's Amylyx Pharmaceuticals position peaked at $23.9M in Q3 2025.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.